( 7.6 ) 7.1 MAOIs Do not use dextromethorphan hydrobromide and quinidine sulfate with monoamine oxidase inhibitors (MAOIs) or in patients who have taken MAOIs within the preceding 14 days [see Contraindications ( 4.3 )] . 7.3 Drugs that Prolong QT and Concomitant CYP3A4 Inhibitors Recommend ECG in patients taking drugs with dextromethorphan hydrobromide and quinidine sulfate that prolong the QT interval and in patients taking concomitant moderate or strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.3 )] . 7.4 SSRIs and Tricyclic Antidepressants Use of dextromethorphan hydrobromide and quinidine sulfate with SSRIs or tricyclic antidepressants increases the risk of ‘serotonin syndrome’ [see Warnings and Precautions ( 5.6 )] .
Source: FDA drug label - dextromethorphan hydrobromide and quinidine sulfate
Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine [DHE] or methysergide) and eletriptan hydrobromide within 24 hours of each other is contraindicated. Concomitant use of other 5-HT1 agonists within 24 hours of eletriptan hydrobromide treatment is contraindicated [see CONTRAINDICATIONS (4)]. 7.2 CYP3A4 Inhibitors Potent CYP3A4 inhibitors significantly increase the exposure of eletriptan hydrobromide.
Source: FDA drug label - eletriptan hydrobromide
Drug Interactions Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including citalopram hydrobromide, and the potential for serotonin syndrome, caution is advised when citalopram is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, opioids, amphetamines, or St.
Source: FDA drug label - citalopram
Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup and MAOI should be avoided (see CONTRAINDICATIONS ).
Source: FDA drug label - brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide
Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS).
Source: FDA drug label - brompheniramine maleate, pseudoephedrine hydrochloride,
Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS ).
Source: FDA drug label - brompheniramine, pseudoephedrine, dextromethorphan
Thus, concomitant administration of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution and MAO inhibitors should be avoided (see CONTRAINDICATIONS ). When given concomitantly with Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, the dose of barbiturates should be reduced by at least one-half, and the dose of narcotics should be reduced by one-quarter to one-half. Epinephrine – Because of the potential for promethazine to reverse epinephrine’s vasopressor effect, epinephrine should NOT be used to treat hypotension associated with Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution overdose.
Source: FDA drug label - promethazine hydrochloride and dextromethorphan hydrobromide